DNA binding partners of YAP/TAZ

  • Kim, Min-Kyu (Department of Biochemistry, College of Medicine, and Institute for Tumor Research, Chungbuk National University) ;
  • Jang, Ju-Won (Department of Biochemistry, College of Medicine, and Institute for Tumor Research, Chungbuk National University) ;
  • Bae, Suk-Chul (Department of Biochemistry, College of Medicine, and Institute for Tumor Research, Chungbuk National University)
  • Received : 2017.12.20
  • Published : 2018.03.31


Hippo signaling plays critical roles in regulation of tissue homeostasis, organ size, and tumorigenesis by inhibiting YES-associated protein (YAP) and PDZ-binding protein TAZ through MST1/2 and LATS1/2 pathway. It is also engaged in cross-talk with various other signaling pathways, including WNT, BMPs, Notch, GPCRs, and Hedgehog to further modulate activities of YAP/TAZ. Because YAP and TAZ are transcriptional coactivators that lack DNA-binding activity, both proteins must interact with DNA-binding transcription factors to regulate target gene's expression. To activate target genes involved in cell proliferation, TEAD family members are major DNA-binding partners of YAP/TAZ. Accordingly, YAP/TAZ were originally classified as oncogenes. However, YAP might also play tumor-suppressing role. For example, YAP can bind to DNA-binding tumor suppressors including RUNXs and p73. Thus, YAP might act either as an oncogene or tumor suppressor depending on its binding partners. Here, we summarize roles of YAP depending on its DNA-binding partners and discuss context-dependent functions of YAP/TAZ.




Supported by : National Research Foundation (NRF) of Korea


  1. Saucedo LJ and Edgar BA (2007) Filling out the Hippo pathway. Nat Rev Mol Cell Biol 8, 613-621
  2. Harvey K and Tapon N (2007) The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer 7, 182-191
  3. Zhao B, Wei X, Li W et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21, 2747-2761
  4. Camargo FD, Gokhale S, Johnnidis JB et al (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17, 2054-2060
  5. Dong J, Feldmann G, Huang J et al (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133
  6. Huang J, Wu S, Barrera J, Matthews K and Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421-434
  7. Fang KS, Barker K, Sudol M and Hanafusa H (1994) A transmembrane protein-tyrosine phosphatase contains spectrin-like repeats in its extracellular domain. J Biol Chem 269, 14056-14063
  8. Zhu C, Li L and Zhao B (2015) The regulation and function of YAP transcription co-activator. Acta Biochim Biophys Sin (Shanghai) 47, 16-28
  9. Sudol M, Bork P, Einbond A et al (1995) Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 270, 14733-14741
  10. Kanai F, Marignani PA, Sarbassova D et al (2000) TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19, 6778-6791
  11. Morin-Kensicki EM, Boone BN, Howell M et al (2006) Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol 26, 77-87
  12. Hall CA, Wang R, Miao J et al (2010) Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 70, 8517-8525
  13. Wang Y, Dong Q, Zhang Q, Li Z, Wang E and Qiu X (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101, 1279-1285
  14. Zhou Z, Zhu JS and Xu ZP (2011) RNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901. Hepatogastroenterology 58, 2156-2161
  15. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C and Hong W (2009) TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 284, 14347-14358
  16. Yu FX, Zhao B, Panupinthu N et al (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791
  17. Mo JS, Yu FX, Gong R, Brown JH and Guan KL (2012) Regulation of the Hippo-YAP pathway by proteaseactivated receptors (PARs). Genes Dev 26, 2138-2143
  18. Liu-Chittenden Y, Huang B, Shim JS et al (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 26, 1300-1305
  19. Zhao B, Kim J, Ye X, Lai ZC and Guan KL (2009) Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res 69, 1089-1098
  20. Zhang H, Pasolli HA and Fuchs E (2011) Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A 108, 2270-2275
  21. Strano S, Munarriz E, Rossi M et al (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276, 15164-15173
  22. Komuro A, Nagai M, Navin NE and Sudol M (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278, 33334-33341
  23. Zagurovskaya M, Shareef MM, Das A et al (2009) EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 28, 1121-1131
  24. Qiao Y, Lin SJ, Chen Y et al (2016) RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer. Oncogene 35, 2664-2674
  25. Yagi R, Chen LF, Shigesada K, Murakami Y and Ito Y (1999) A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 18, 2551-2562
  26. Ferrigno O, Lallemand F, Verrecchia F et al (2002) Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene 21, 4879-4884
  27. Kurisaki A, Kose S, Yoneda Y, Heldin CH and Moustakas A (2001) Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. Mol Biol Cell 12, 1079-1091
  28. Vassilev A, Kaneko KJ, Shu H, Zhao Y and DePamphilis ML (2001) TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 15, 1229-1241
  29. Xiao JH, Davidson I, Matthes H, Garnier JM and Chambon P (1991) Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1. Cell 65, 551-568
  30. Kaneko KJ and DePamphilis ML (1998) Regulation of gene expression at the beginning of mammalian development and the TEAD family of transcription factors. Dev Genet 22, 43-55<43::AID-DVG5>3.0.CO;2-7
  31. Jacquemin P, Sapin V, Alsat E, Evain-Brion D, Dolle P and Davidson I (1998) Differential expression of the TEF family of transcription factors in the murine placenta and during differentiation of primary human trophoblasts in vitro. Dev Dyn 212, 423-436<423::AID-AJA10>3.0.CO;2-1
  32. Li Z, Zhao B, Wang P et al (2010) Structural insights into the YAP and TEAD complex. Genes Dev 24, 235-240
  33. Chen L, Loh PG and Song H (2010) Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway. Protein Cell 1, 1073-1083
  34. Zhao B, Ye X, Yu J et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22, 1962-1971
  35. Mo JS, Meng Z, Kim YC et al (2015) Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol 17, 500-510
  36. Zhao B, Lei QY and Guan K L (2008) The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 20, 638-646
  37. Zhou Y, Huang T Cheng AS, Yu J, Kang W and To KF (2016) The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis. Int J Mol Sci 17, 1-15
  38. Hiemer SE, Szymaniak AD and Varelas X (2014) The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem 289, 13461-13474
  39. Rashidian J, Le Scolan E, Ji X et al (2015) Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. Sci Signal 8, ra14
  40. You B, Yang YL, Xu Z et al (2015) Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget 6, 4357-4368
  41. Nguyen LT, Tretiakova MS, Silvis MR et al (2015) ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. Cancer Cell 27, 797-808
  42. Chan LH, Wang W, Yeung W, Deng Y, Yuan P and Mak KK (2014) Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene 33, 4857-4866
  43. Zhang W, Nandakumar N, Shi Y et al (2014) Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 7, ra42
  44. Cai H and Xu Y (2013) The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 11, 31
  45. Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T and Gera J (2015) Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. J Biol Chem 290, 19387-19401
  46. Yu FX, Luo J, Mo JS et al (2014) Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25, 822-830
  47. Serrano I, McDonald PC, Lock F, Muller WJ and Dedhar S (2013) Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun 4, 2976
  48. Wang J, Park JS, Wei Y et al (2013) TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPalpha function. Mol Cell 51, 211-225
  49. Liu AM, Xu Z and Luk JM (2012) An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets 16, 243-247
  50. Fernandez LA, Squatrito M, Northcott P et al (2012) Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 31, 1923-1937
  51. Fujii M, Nakanishi H, Toyoda T et al (2012) Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFbeta signaling and defects in the Hippo signaling cascade. Cell Cycle 11, 3373-3379
  52. Xia Y, Zhang YL, Yu C, Chang T and Fan HY (2014) YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS One 9, e109575
  53. Chen L, Chan SW, Zhang X et al (2010) Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev 24, 290-300
  54. Fossdal R, Jonasson F, Kristjansdottir GT et al (2004) A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Hum Mol Genet 13, 975-981
  55. Kitagawa M (2007) A Sveinsson's chorioretinal atrophyassociated missense mutation in mouse Tead1 affects its interaction with the co-factors YAP and TAZ. Biochem Biophys Res Commun 361, 1022-1026
  56. Zhang J, Ji JY, Yu M et al (2009) YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11, 1444-1450
  57. Yang N, Morrison CD, Liu P et al (2012) TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 11, 2922-2930
  58. Neto-Silva RM, de Beco S and Johnston LA (2010) Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Dev Cell 19, 507-520
  59. Li C, Srivastava RK, Elmets CA, Afaq F and Athar M (2013) Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein. Biochem Biophys Res Commun 438, 607-612
  60. Thongon N, Castiglioni I, Zucal C et al (2016) The GSK3beta inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. Oncotarget 7, 26551-26566
  61. Pobbati AV and Hong W (2013) Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther 14, 390-398
  62. Zawacka-Pankau J, Kostecka A, Sznarkowska A, Hedstrom E and Kawiak A (2010) p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle 9, 720-728
  63. Basu S, Totty NF, Irwin MS, Sudol M and Downward J (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11, 11-23
  64. Strano S, Monti O, Pediconi N et al (2005) The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 18, 447-459
  65. Oka T, Mazack V and Sudol M (2008) Mst2 and Lats kinases regulate apoptotic function of Yes kinaseassociated protein (YAP). J Biol Chem 283, 27534-27546
  66. Rossi M, De Laurenzi V, Munarriz E et al (2005) The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24, 836-848
  67. Levy D, AdamovichY, Reuven N and Shaul Y (2007) The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 14, 743-751
  68. Lapi E, Di Agostino S, Donzelli S et al (2008) PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 32, 803-814
  69. Bernassola F, Salomoni P, Oberst A et al (2004) Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 199, 1545-1557
  70. Okazaki T, Kageji T, Kuwayama K et al (2012) Upregulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAPmediated apoptosis in glioblastoma. Cancer Lett 323, 199-207
  71. Cottini F, Hideshima T, Xu C et al (2014) Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med 20, 599-606
  72. Levy D, Adamovich Y, Reuven N and Shaul Y (2008) Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 29, 350-361
  73. Keshet R, Adler J, Ricardo Lax I et al (2015) c-Abl antagonizes the YAP oncogenic function. Cell Death Differ 22, 935-945
  74. Rosenbluh J, Nijhawan D, Cox AG et al (2012) beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473
  75. Zaidi SK, Sullivan AJ, Medina R et al (2004) Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 23, 790-799
  76. Omerovic J, Puggioni EM, Napoletano S et al (2004) Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 294, 469-479
  77. Haskins JW, Nguyen DX and Stern DF (2014) Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Sci Signal 7, ra116
  78. Schuchardt BJ, Bhat V, Mikles DC, McDonald CB, Sudol M and Farooq A (2014) Molecular basis of the binding of YAP transcriptional regulator to the ErbB4 receptor tyrosine kinase. Biochimie 101, 192-202
  79. Aqeilan RI, Kuroki T, Pekarsky Y et al (2004) Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 10, 3053-3058
  80. Aqeilan RI, Donati V, Gaudio E et al (2007) Association of Wwox with ErbB4 in breast cancer. Cancer Res 67, 9330-9336
  81. Aqeilan RI, Hassan MQ, de Bruin A et al (2008) The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem 283, 21629-21639
  82. Aqeilan RI, Donati V, Palamarchuk A et al (2005) WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65, 6764-6772
  83. Del Mare S and Aqeilan RI (2015) Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep 5, 12959
  84. Das A, Chendil D, Dey S et al (2001) Ionizing radiation down-regulates p53 protein in primary Egr-1-/- mouse embryonic fibroblast cells causing enhanced resistance to apoptosis. J Biol Chem 276, 3279-3286
  85. Murakami M, Nakagawa M, Olson EN and Nakagawa O (2005) A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci U S A 102, 18034-18039
  86. Derynck R and Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584
  87. Varelas X, Sakuma R, Samavarchi-Tehrani P et al (2008) TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 10, 837-848
  88. Varelas X, Samavarchi-Tehrani P, Narimatsu M et al (2010) The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev Cell 19, 831-844
  89. Grannas K, Arngarden L, Lonn P et al (2015) Crosstalk between Hippo and TGFbeta: Subcellular Localization of YAP/TAZ/Smad Complexes. J Mol Biol 427, 3407-3415
  90. Komori T, Yagi H, Nomura S et al (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764
  91. Otto F, Thornell AP, Crompton T et al (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89, 765-771
  92. Marzia M, Sims NA, Voit S et al (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151, 311-320
  93. Soriano P, Montgomery C, Geske R and Bradley A (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702
  94. Hong JH, Hwang ES, McManus MT et al (2005) TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309, 1074-1078
  95. Li QL, Ito K, Sakakura C et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124
  96. Jang JW, Kim MK, Lee YS et al (2017) RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3. Oncogene 36, 999-1011
  97. Zender L, Spector MS, Xue W et al (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253-1267
  98. Barry ER, Morikawa T, Butler BL et al (2013) Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106-110

Cited by

  1. Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms vol.7, pp.1, 2018,
  2. YAP/TAZ Activation as a Target for Treating Metastatic Cancer vol.10, pp.4, 2018,
  3. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis vol.294, pp.7, 2018,